A surge in demand for menopause hormone therapy (MHT) has outpaced supply, forcing New Zealand’s drug-funding agency Pharmac to temporarily ration supplies this week. While awareness of MHT’s benefits has grown—backed by updated clinical guidelines and long-term trial data—gaps in doctor training and outdated medical education are leaving millions of women without proper care.
Why Demand Is Rising—and Why Supplies Can’t Keep Up
Two decades ago, the Women’s Health Initiative trial (published in 2002) sent shockwaves through medicine, linking combination hormone therapy to higher risks of breast cancer, stroke, and blood clots. For years, doctors prescribed MHT only to women with severe symptoms—and even then, at the lowest possible doses for the shortest duration. But follow-up data from the same trial, released in 2023, showed that after 18 years, overall mortality rates were identical between women who took five years of MHT and those who didn’t. Transdermal estrogen treatments (patches, gels) have since been shown to carry minimal cardiovascular risks, prompting a shift in guidelines.
Today, most women prescribed MHT receive body-identical hormones—estrogen patches or gels, combined with progesterone—to relieve hot flashes, night sweats, and bone loss. The therapy is now also recognized as a first-line defense against osteoporosis. Yet the supply chain is struggling: Pharmac’s rationing reflects a global shortage, with manufacturers unable to meet the sudden spike in prescriptions.
The “Window of Opportunity” and Why Timing Matters
Expert consensus now emphasizes a critical window for starting MHT: ideally within 10 years of a woman’s last menstrual period. According to Dr. Shaya Taghechian, a women’s hormone therapy specialist at Georgia Urology, “Hormone replacement therapy should be started either perimenopausally or, ideally, within 10 years of a woman’s last menstrual period.” This period—dubbed the “window of opportunity”—maximizes symptom relief and potential protective benefits for heart and bone health.
“Hormone replacement therapy should be started either perimenopausally or, ideally, within 10 years of a woman’s last menstrual period.”
Starting later—especially 20 years after menopause—may increase cardiovascular risks, Taghechian warns. Yet the urgency of this window collides with a harsh reality: many women don’t even know they’re eligible for optimal treatment. A 2023 survey found that 60% of U.S. women aged 45–55 had never discussed menopause with a doctor, and only 20% had heard of the “window of opportunity.”
Hormone Therapy vs. “Replacement Therapy”: What’s the Difference?
The medical language around MHT has evolved to reflect a nuanced understanding of its role. As Dr. Stephanie Faubion, director of the Mayo Clinic’s Center for Women’s Health, explains, “We call it hormone therapy, and the reason for that is we are not trying to replace what the ovary used to make. We’re only trying to give enough estrogen to manage symptoms.”
“We’re only trying to give enough estrogen to manage symptoms.”
For more on this story, see Perimenopause Misinformation Puts Women at Risk of Unintended Pregnancy and Misdiagnosis.
This distinction matters. For women experiencing natural menopause in their 50s, MHT is about symptom management, not disease prevention. The therapy’s goal is relief—not restoration. But for the roughly 5% of women who experience premature or early menopause (before age 40 or between 40–45), the approach shifts. Here, Faubion notes, “we are trying to replace what they lost” to prevent long-term consequences like heart disease, bone density loss, and cognitive decline.
Training Gaps Leave Millions Without Proper Care
The supply shortage is only part of the problem. A deeper crisis looms in medical education. In the UK, four out of ten medical schools lack mandatory menopause education, and U.S. obstetrics and gynecology programs often omit dedicated modules on midlife care. The result? Many doctors—especially younger ones—lack the confidence to discuss MHT with patients or prescribe it effectively.
This gap isn’t new. After the 2002 Women’s Health Initiative findings, MHT prescriptions plummeted. Doctors stopped offering it unless symptoms were severe, and medical schools reduced or eliminated menopause training. Now, as demand rebounds, the system is playing catch-up. A 2024 survey of U.S. primary care physicians found that 40% reported feeling unprepared to counsel women on MHT, and 30% cited lack of time as a barrier to discussing the topic.
What Happens Next: Supply, Policy, and the Road Ahead
Short-term, Pharmac’s rationing may ease as manufacturers scale up production.
- Expanding medical education: The UK and U.S. are beginning to integrate menopause training into residency programs, but progress is slow. New Zealand’s Pharmac is piloting a national campaign to upskill primary care providers, with plans to roll out standardized protocols by 2027.
- Clarifying guidelines: The North American Menopause Society and the World Health Organization are reviewing global MHT protocols to standardize dosing, duration, and risk assessments. A draft update, expected later this year, may address the “window of opportunity” more explicitly.
- Breaking stigma: Public health campaigns—like AARP’s recent initiative—are framing menopause as a normal life stage, not a medical emergency. But cultural shifts take time. In Japan, where menopause is rarely discussed, only 12% of women aged 50–59 have ever used MHT, compared to 30% in the U.S.
The stakes are high. Menopause affects half the global population, yet 85% of women experience symptoms severe enough to disrupt daily life. For those who can access MHT, the therapy is up to 95% effective at managing hot flashes, sleep disturbances, and mood swings. But without trained providers and reliable supply chains, millions remain untreated—and the health consequences ripple across generations.
For now, women should ask their doctors about MHT options, but with caution. Not all symptoms require treatment, and risks vary by age, health history, and type of therapy. As Faubion advises, “The decision to start hormone therapy should be made on an annual basis between a well-informed woman and her health practitioner.” The conversation is changing—but the care gap persists.
